Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899353 · ClinicalTrials.gov registry record · Phase 2
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
A Phase 2 study, sponsored by Marshall University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00899353: Clinical Trial Phase 2 study, sponsored by Marshall University.
NCT00899353 is a Phase 2 study that was terminated before completion, run by Marshall University. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00899353, a Phase 2 study, was terminated before completion, sponsored by Marshall University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose disease does not currently require treatment. The primary aim of the study is to determine if the Omega 3 supplementation will help prevent or delay progression of the disease to a stage that requires treatment.
Primary Outcome
Peripheral lymphocytes were isolated from the blood using Ficoll-Paque gradient. Nuclear Factor Kappa B activation was analyzed using Thermo Scientific Transcription Factor kit for NFkB p50, according to manufacturer's protocol. Protein extracts containing 1-15µg of protein/well were added in triplicates. Luminescence resulting from a reaction with bound NFkB was detected using a Berthold Centro LB960 Luminometer and analyzed with MikroWin 2000 ver. 1.08. NFkB activity was normalized by luminesc
Interventions
- DIETARY_SUPPLEMENT Omega 3 Fatty Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Why NCT00899353 stopped before completion
NCT00899353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Omega 3 Fatty Acid is the first listed.
NCT00899353 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00899353 about?
NCT00899353 is a clinical study titled "Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)". Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose disease does not currently require treatment. The primary aim of the s...
What is the current status of trial NCT00899353?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2008-08. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00899353?
The interventions under investigation include: Omega 3 Fatty Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00899353?
This trial is sponsored by Marshall University, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00899353's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia